Jump to content
Sclero Forums
Sign in to follow this  
Joelf

Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus (SLE).

Recommended Posts

Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus (SLE).

 

The data suggest that targeting plasmacytoid DCs may be beneficial for patients with SLE, especially those with cutaneous manifestations. PubMed, J Clin Invest, 2019 Mar 1;129(3):1359-1371. (Also see Antibodies in Lupus)

 

This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles. 


Jo Frowde

ISN Board Member

ISN Secretary of the Board

ISN Assistant Webmaster

SD World Webmaster

ISN Sclero Forums Manager

ISN News Manager

ISN Hotline Support Specialist

International Scleroderma Network (ISN)

Share this post


Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Sign in to follow this  

×
×
  • Create New...